868459AD0
Supernus Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A maker of brain and nervous-system medicines, Supernus develops and sells branded treatments for ADHD, Parkinson's disease, epilepsy, and postpartum depression—brands like Qelbree, GOCOVRI, Trokendi XR, and ZURZUVAE. It began in 2005 as a spin-out of Shire Laboratories, founded by Jack Khattar, who then bought the very business he had led. Its name comes from Latin for "from above," a fitting label for a company born out of the lab it once ran.
CONVERTIBLEUnderlying: SUPNCUSIP: 868459AD0HealthcareUS1 derivative reporter
0.625% Convertible Senior Notes due 2023, matured and repaid April 1, 2023
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
